Researchers reported in Nature Communications that inhibiting LRBA induces CTLA‑4 degradation and enhances anti‑tumor immunity in preclinical models. The study elucidates a pathway by which LRBA stabilizes CTLA‑4 protein, suggesting LRBA as a druggable node to modulate a key immune checkpoint distinct from direct CTLA‑4 antibodies. The work includes genetic perturbation and functional assays showing increased T‑cell activation and improved tumor control when LRBA is targeted. For immunotherapy developers, LRBA inhibitors or degraders could offer an alternative or complement to CTLA‑4 blocking antibodies, with implications for dosing, toxicity profiles, and combination strategies.